MSF's publications are an expression of our belief in the principle of témoignage, or bearing witness, and the belief that we are accountable to those we work for and with. Sharing news about our activities and reflecting on them, offering critiques when necessary, are therefore crucial aspects of our work.

View and download these publications below.

To view the U.S. Annual Reports or International Activity Reports, please visit the Annual Reports page.

Country/Region

10.30.2014

A survey of TB diagnostic and treatment practices in eight countries, October 2014.

MSF briefing paper, December 2014

What began in 2011 in Syria as protests inspired by the Arab Spring has become an entrenched and bloody conflict that shows no sign of resolution. Today, with an estimated 200,000 people killed and 7.6 million people displaced within the country and 3.2 million refugees registered outside, Syria is seen as the world’s most grave humanitarian disaster. In the face of this crisis, the previously functioning health system has collapsed and scores of thousands of medical staff have fled.

Iraq experienced a dramatic surge in violence in 2014 that triggered successive large-scale waves of displacement. More than 2.6 million people are said to have fled war-torn the central and northern areas of Iraq, particularly Al-Anbar, Ninawa, Salah Al-Din, Kirkuk and Diyala governorates.

April 07, 2015

MSF published evidence from its community-based management of acute malnutrition program in Bihar, India, which revealed that it has successfully achieved a cure rate of 88.4 percent among severely acute malnourished children who completed treatment.

January 26, 2015

Secret meeting this week in New York a chance to remove provisions that threaten access to lifesaving medicines.

January 23, 2015

New intellectual property "think tank" draft policy already showing alarming trend.

January 14, 2015

The Indian Patent Controller today rejected one of Gilead’s key patent applications, which covered the drug sofosbuvir, used to treat hepatitis C (HCV). The oral drug, which first received regulatory approval in the US in November 2013, and has been priced by Gilead at US$84,000 for a treatment course, or $1,000 per pill in the US, has caused a worldwide debate on the pricing of patented medicines. A study from Liverpool University showed that sofosbuvir could be produced for as little as $101 for a three-month treatment course.

October 31, 2014

Doctors Without Borders/Médecins Sans Frontières (MSF) would like to submit the following written comments to the 2014 United States Trade Representative (USTR) Special 301 Out-of-Cycle Review of India’s intellectual property legal regime and policies.

September 26, 2014

As Indian prime minister Narendra Modi makes his first official visit to the US, MSF is urging the Indian government to resist US pressure to drop the use of public health safeguards in its intellectual property laws.

September 15, 2014

 

On September 15, Gilead Sciences is expected to announce agreements with a handful of Indian pharmaceutical manufacturers to produce and sell generic versions of two new Hepatitis C drugs—sofosbuvir and ledipasvir. Approximately 180 million people live with Hepatitis C today, with 350,000 people dying annually of the disease.

May 15, 2014

 

Although tuberculosis (TB) is preventable and curable, it is the second-biggest infectious disease killer behind HIV and claims nearly 1.3 million lives each year.

The spread of drug-resistant strains of the disease is increasingly recognized as a public health emergency. Drug-resistant tuberculosis (DR-TB) is an umbrella term that refers to tuberculosis strains which resist the drugs routinely used to treat conventional TB.

October 30, 2013

In the mountainous region of Nagaland, northeast India, Doctors Without Borders/Médecins Sans Frontières (MSF) is working with local groups and health authorities to treat people with drug-resistant tuberculosis (DR-TB), a form of the disease that does not respond to the two main drugs used to treat TB. The two-year regimen for treating DR-TB is extremely arduous and can cause patients to become blind or deaf and can cause organ failure. MSF is calling for better diagnosis and treatment for DR-TB. Support the Test Me, Treat Me DR-TB Manifesto. Sign now at http://msfaccess.org/TBmanifesto/.

October 10, 2013

Outgoing International President MSF Dr. Unni Karunakara is taking to the road on a bicycle to travel 5000 kilometers in India to spark dialogue on health, health care, and humanitarianism.

Pages